ImmunomeInc Net Income Applicable To Common Shares from 2010 to 2024
| IMNM Stock | USD 14.97 0.28 1.91% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -33.8 M | Current Value -32.1 M | Quarterly Volatility 11.1 M |
Check ImmunomeInc financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmunomeInc main balance sheet or income statement drivers, such as Net Interest Income of 2.9 M, Interest Income of 2.9 M or Depreciation And Amortization of 667.7 K, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0016 or PTB Ratio of 1.52. ImmunomeInc financial statements analysis is a perfect complement when working with ImmunomeInc Valuation or Volatility modules.
ImmunomeInc | Net Income Applicable To Common Shares |
Latest ImmunomeInc's Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of ImmunomeInc over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. ImmunomeInc's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ImmunomeInc's overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
ImmunomeInc Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | (15,130,606) | |
| Coefficient Of Variation | (73.56) | |
| Mean Deviation | 9,367,608 | |
| Median | (7,845,000) | |
| Standard Deviation | 11,130,667 | |
| Sample Variance | 123.9T | |
| Range | 29.7M | |
| R-Value | (0.83) | |
| Mean Square Error | 42.2T | |
| R-Squared | 0.68 | |
| Significance | 0.0001 | |
| Slope | (2,057,716) | |
| Total Sum of Squares | 1734.5T |
ImmunomeInc Net Income Applicable To Common Shares History
About ImmunomeInc Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include ImmunomeInc income statement, its balance sheet, and the statement of cash flows. ImmunomeInc investors use historical funamental indicators, such as ImmunomeInc's Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although ImmunomeInc investors may use each financial statement separately, they are all related. The changes in ImmunomeInc's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ImmunomeInc's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ImmunomeInc Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ImmunomeInc. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -33.8 M | -32.1 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ImmunomeInc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ImmunomeInc's short interest history, or implied volatility extrapolated from ImmunomeInc options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of ImmunomeInc Correlation against competitors. To learn how to invest in ImmunomeInc Stock, please use our How to Invest in ImmunomeInc guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for ImmunomeInc Stock analysis
When running ImmunomeInc's price analysis, check to measure ImmunomeInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunomeInc is operating at the current time. Most of ImmunomeInc's value examination focuses on studying past and present price action to predict the probability of ImmunomeInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunomeInc's price. Additionally, you may evaluate how the addition of ImmunomeInc to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is ImmunomeInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmunomeInc. If investors know ImmunomeInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmunomeInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.38) | Revenue Per Share 0.706 | Return On Assets (0.21) | Return On Equity (1.56) |
The market value of ImmunomeInc is measured differently than its book value, which is the value of ImmunomeInc that is recorded on the company's balance sheet. Investors also form their own opinion of ImmunomeInc's value that differs from its market value or its book value, called intrinsic value, which is ImmunomeInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmunomeInc's market value can be influenced by many factors that don't directly affect ImmunomeInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmunomeInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunomeInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunomeInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.